Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease ; year:2020
ChemistryOpen ; (2020)
- Urheber
-
Xu, Chenshu
Zou, Haoman
Yu, Xi
Xie, Yazhou
Cai, Jiaxin
Shang, Qi
Ouyang, Na
Wang, Yinan
Xu, Pan
He, Zhendan
Wu, Haiqiang
- DOI
-
10.1002/open.202000235
- URN
-
urn:nbn:de:101:1-2021020510543319404821
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:38 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Xu, Chenshu
- Zou, Haoman
- Yu, Xi
- Xie, Yazhou
- Cai, Jiaxin
- Shang, Qi
- Ouyang, Na
- Wang, Yinan
- Xu, Pan
- He, Zhendan
- Wu, Haiqiang
Ähnliche Objekte (12)
Repurposing FDA-approved drugs for anti-aging therapies
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
QUADrATiC: scalable gene expression connectivity mapping for repurposing FDA-approved therapeutics
Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells
Repurposing of FDA approved ring systems through bi-directional target-ring system dual screening
Repurposing of approved cardiovascular drugs
Repurposing FDA-approved drugs targeting FZD10 in nasopharyngeal carcinoma: insights from molecular dynamics simulations and experimental validation
The First FDA-Approved Antibody-Drug Conjugate
Repurposing FDA‐Approved Drugs for Temozolomide‐Resistant IDH1 Mutant Glioma Using High‐Throughput Miniaturized Screening on Droplet Microarray Chip
Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
Repurposing FDA-approved drugs for anti-aging therapies
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
QUADrATiC: scalable gene expression connectivity mapping for repurposing FDA-approved therapeutics
Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells
Repurposing of FDA approved ring systems through bi-directional target-ring system dual screening
Repurposing of approved cardiovascular drugs
Repurposing FDA-approved drugs targeting FZD10 in nasopharyngeal carcinoma: insights from molecular dynamics simulations and experimental validation
The First FDA-Approved Antibody-Drug Conjugate
Repurposing FDA‐Approved Drugs for Temozolomide‐Resistant IDH1 Mutant Glioma Using High‐Throughput Miniaturized Screening on Droplet Microarray Chip
Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
Repurposing FDA-approved drugs for anti-aging therapies
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
QUADrATiC: scalable gene expression connectivity mapping for repurposing FDA-approved therapeutics
Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells
Repurposing of FDA approved ring systems through bi-directional target-ring system dual screening
Repurposing of approved cardiovascular drugs
Repurposing FDA-approved drugs targeting FZD10 in nasopharyngeal carcinoma: insights from molecular dynamics simulations and experimental validation
The First FDA-Approved Antibody-Drug Conjugate
Repurposing FDA‐Approved Drugs for Temozolomide‐Resistant IDH1 Mutant Glioma Using High‐Throughput Miniaturized Screening on Droplet Microarray Chip